IDXX vs PAHC vs ZTS Stock Comparison

Idexx Laboratories, Phibro Animal Health and Zoetis Prices as of Nov 4, 2026 Peers: Industry group
ZTS Zoetis Inc.
$88.63 +24.1% 1M -28.8% 1Y
Market cap
$34.08B
P/E
13.0x
Revenue (TTM)
$9.52B
Div. yield
0.03%
Animal Health Healthcare
3 wins

Head to Head

12 decided of 12

Idexx Laboratories leads on 6 of the 12 questions below (Idexx Laboratories 6, Zoetis 3, Phibro Animal Health 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionIDXXPAHCZTSLeader
Larger companyMarket capitalisation $52.78B $1.45B $34.08B IDXX
Cheaper on earningsLower P/E, profitable companies only 44.6x 14.5x 13.0x ZTS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 44.7x 11.5x 15.1x PAHC
Faster revenue growthRevenue growth, trailing twelve months +11.9% +17.1% +1.5% PAHC
More profitableNet margin, trailing twelve months 25.4% 6.6% 27.5% ZTS
Better return on capitalReturn on invested capital 45.4% 14.2% 23.4% IDXX
Less leveragedLower net debt / EBITDA 0.4x 2.1x 1.8x IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.03% ZTS
Better 1-year returnPrice return, last 12 months -3.3% -6.4% -28.8% IDXX
Better 5-year returnAnnualised price return, 5 years +1.9%/yr +12.0%/yr -16.4%/yr PAHC
Less volatileAnnualised volatility, 1 year 35.6% 55.6% 38.8% IDXX
Higher overall scoreMean of the five percentile scores vs peers 77/100 68/100 71/100 IDXX

Percentile Scorecard

IDXXPAHCZTS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisIDXXPAHCZTS
Valuation 75 #159 of 634 92 #50 of 634 87 #84 of 634
Growth 72 #173 of 607 85 #90 of 607 51 #300 of 607
Profitability 97 #17 of 557 85 #84 of 557 96 #24 of 557
Financial Health 48 #343 of 654 26 #483 of 654 35 #429 of 654
Shareholder Returns 94 #27 of 400 53 #190 of 400 88 #51 of 400
Overall 77 68 71
  • IDXX ranked among 671 companies in Pharmaceuticals and Biotechnology
  • PAHC ranked among 671 companies in Pharmaceuticals and Biotechnology
  • ZTS ranked among 671 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodIDXXPAHCZTSSPY
1 month +32.5%+6.0%+24.1% -1.0%
3 months +19.5%+9.5%+19.1% -0.4%
6 months +20.6%-32.6%-20.3% +4.5%
Year to date +3.3%+5.5%-29.6% +12.4%
1 year -3.3%-6.4%-28.8% +13.6%
3 years +62.7%+219.5%-45.4% +76.4%
3 years, per year +17.6%+47.3%-18.3% +20.8%
5 years +9.6%+76.3%-59.1% +63.7%
5 years, per year +1.9%+12.0%-16.4% +10.4%
10 years +557.7%+50.5%+77.5% +267.7%
10 years, per year +20.7%+4.2%+5.9% +13.9%

Risk

MeasureIDXXPAHCZTSSPY
Volatility, 1Y 35.6%55.6%38.8% 12.8%
Downside volatility, 1Y 32.0%59.8%45.0% 12.7%
Beta vs S&P 500, 1Y 0.790.750.43 1.00
Return / volatility, 1Y -0.09-0.11-0.74 1.06
Max drawdown, 5Y -50.9%-57.9%-72.0% -25.4%
From 52-week high -8.9%-33.8%-32.4% -1.6%
52-week high $766.68$59.58$131.10 $779.14
52-week low $504.70$28.52$69.12 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleIDXXPAHCZTS
P/E now vs peer median 46.6xmedian 18.0x 16.0xmedian 18.0x 14.1xmedian 18.0x
P/S now vs peer median 11.8xmedian 9.1x 1.1xmedian 9.1x 3.9xmedian 9.1x
EV/EBITDA now vs peer median 33.5xmedian 16.2x 8.4xmedian 16.2x 10.8xmedian 16.2x
P/FCF now vs peer median 42.2xmedian 21.7x 162.0xmedian 21.7x 15.8xmedian 21.7x
P/B now vs peer median 29.4xmedian 2.2x 4.1xmedian 2.2x 11.7xmedian 2.2x
PEG now vs peer median 3.07median 0.38 0.36median 0.38 1.50median 0.38

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsIDXXPAHCZTS
Revenue $4.66B $1.52B $9.52B
Gross profit $2.92B $512.52M $6.81B
Operating income $1.51B $194.40M $3.59B
Net income $1.18B $99.72M $2.62B
Free cash flow $1.30B $9.87M $2.32B
R&D $266.87M – $722.00M
EPS (diluted) $14.96 $2.43 $6.26
Cash & equivalents $197.54M $61.42M $1.48B
Total debt $848.88M $616.79M $9.05B
Shares (diluted) 79.05M 40.96M 417.70M
Enterprise value $52.01B $1.13B $25.93B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricIDXXPAHCZTS
P/E 46.6x 16.0x 14.1x
P/FCF 42.2x 162.0x 15.8x
P/Operating cash flow 38.8x 23.2x 12.9x
P/S 11.8x 1.1x 3.9x
P/B 29.4x 4.1x 11.7x
P/Tangible book 31.4x 4.5x 16.5x
EV/EBITDA 33.5x 8.4x 10.8x
EV/EBIT 37.0x 11.0x 12.3x
EV/Revenue 11.9x 1.4x 4.6x
EV/FCF 42.7x 216.3x 19.0x
EV/Operating cash flow 39.2x 30.9x 15.5x
PEG (3Y EPS CAGR) 3.07 0.36 1.50

Growth

14 metrics
MetricIDXXPAHCZTS
Revenue growth (1Y) 11.9% 17.1% 1.5%
Revenue CAGR (3Y) 9.1% 15.8% 5.0%
Gross profit growth (1Y) 13.7% 28.1% 1.8%
Gross profit CAGR (3Y) 10.8% 19.8% 5.7%
Operating income growth (1Y) 15.3% 76.0% -0.1%
Operating income CAGR (3Y) 11.8% 39.3% 5.2%
Net income growth (1Y) 15.1% 106.6% 0.6%
Net income CAGR (3Y) 12.8% 45.2% 5.7%
EPS growth (1Y) 17.4% 105.2% 7.7%
EPS CAGR (3Y) 15.1% 44.6% 9.4%
Operating cash flow growth (1Y) 30.4% -13.9% -4.6%
Operating cash flow CAGR (3Y) 19.6% 73.0% 12.4%
Free cash flow growth (1Y) 35.3% -76.4% 2.1%
Free cash flow CAGR (3Y) 24.2% 31.2% 21.7%

Profitability

14 metrics
MetricIDXXPAHCZTS
Gross margin 62.7% 33.8% 71.5%
EBITDA margin 35.7% 16.8% 42.8%
Operating margin 32.3% 12.8% 37.7%
Pretax margin 31.7% 9.0% 34.4%
Net margin 25.4% 6.6% 27.5%
FCF margin 28.0% 0.6% 24.3%
Operating cash flow margin 30.4% 4.5% 29.8%
Return on equity 67.9% 26.7% 82.0%
Return on assets 33.1% 6.8% 17.3%
Return on invested capital 45.4% 14.2% 23.4%
Return on capital employed 65.2% 16.8% 27.5%
Asset turnover 1.3x 1.0x 0.6x
Cash conversion (OCF / net income) 1.2x 0.7x 1.1x
Stock comp / revenue 1.4% 0.1% 1.0%

Financial Health

11 metrics
MetricIDXXPAHCZTS
Debt / assets 22.9% 41.1% 60.0%
Debt / equity 0.5x 1.6x 2.9x
Net debt / EBITDA 0.4x 2.1x 1.8x
Debt / FCF 0.7x 62.5x 3.9x
Liabilities / assets 49.6% 74.3% 79.1%
Equity / assets 50.4% 25.7% 20.9%
Interest coverage 43.5x 4.2x 15.1x
Current ratio 1.2x 3.0x 3.1x
Quick ratio 0.7x 1.1x 1.6x
Cash ratio 0.2x 0.3x 0.8x
Altman Z-score 23.41 3.12 4.97

Shareholder Returns

7 metrics
MetricIDXXPAHCZTS
Dividend yield – 1.2% 2.4%
Net buyback yield 1.7% – 9.9%
Shareholder yield 1.7% 1.2% 12.3%
Payout ratio (earnings) – 19.5% 34.0%
Payout ratio (FCF) – 197.3% 38.4%
Dividend growth (1Y) – 0.1% 6.1%
Dividend CAGR (3Y) – 0.0% 10.9%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusIDXXPAHCZTS
Forward P/E 44.7xFY2026 11.5xFY2027 15.1xFY2026
EPS, next fiscal year $15.63FY2026 $3.42FY2027 $5.86FY2026
EPS growth, next FY +19.5%FY2026 +6.2%FY2027 -8.6%FY2026
EPS growth, the year after +12.9% +9.6% +13.0%
Revenue, next fiscal year $5.00BFY2026 $1.53BFY2027 $9.57BFY2026
Revenue growth, next FY +16.3%FY2026 +0.6%FY2027 +1.0%FY2026
Revenue growth, the year after +0.6% -0.2% -7.9%
IDXX estimates →PAHC estimates →ZTS estimates →

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersIDXXPAHCZTS
Held by institutions 93.6% 99.1% 94.7%
Institutions holding 1,291 210 1,419
Change in shares held, QoQ +4.1% +3.0% -2.6%
Institutions buying 589 117 675
Institutions selling 496 75 583
Buyers to sellers 1.19 1.56 1.16
IDXX holders →PAHC holders →ZTS holders →

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

IDXXPAHCZTS
IDXX 1.00 0.27 0.49
PAHC 0.27 1.00 0.64
ZTS 0.49 0.64 1.00

Add a Peer

Largest companies in the same industry
IDXX · Animal Health
+MRKMerck +CORCencora +ELANElanco Animal Health +CHWYChewy +NEOGNeogen +BFLYButterfly Network +ANIKAnika Therapeutics +ZOMDFZomedica
Plot all 33 Animal Health stocks →

Related Comparisons

IDXX vs MRKMerck IDXX vs CORCencora IDXX vs ELANElanco Animal Health IDXX vs CHWYChewy

Frequently Asked Questions

Which is bigger, IDXX, PAHC and ZTS?

Idexx Laboratories (IDXX) is the largest by market capitalisation: Idexx Laboratories (IDXX) $52.78B, Phibro Animal Health (PAHC) $1.45B, Zoetis (ZTS) $34.08B.

Which stock is cheaper, IDXX, PAHC and ZTS?

Zoetis (ZTS) trades on the lowest price-to-earnings ratio (Idexx Laboratories (IDXX) 44.6x, Phibro Animal Health (PAHC) 14.5x, Zoetis (ZTS) 13.0x). On next year's consensus earnings, Phibro Animal Health (PAHC) is cheapest (Idexx Laboratories (IDXX) 44.7x, Phibro Animal Health (PAHC) 11.5x, Zoetis (ZTS) 15.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Phibro Animal Health (PAHC) grew revenue fastest over the trailing twelve months: Idexx Laboratories (IDXX) +11.9%, Phibro Animal Health (PAHC) +17.1%, Zoetis (ZTS) +1.5%.

Which company is more profitable?

Zoetis (ZTS) has the highest net margin (Idexx Laboratories (IDXX) 25.4%, Phibro Animal Health (PAHC) 6.6%, Zoetis (ZTS) 27.5%). On return on invested capital, Idexx Laboratories (IDXX) leads (Idexx Laboratories (IDXX) 45.4%, Phibro Animal Health (PAHC) 14.2%, Zoetis (ZTS) 23.4%).

Which stock has performed better?

Over the past year Idexx Laboratories (IDXX) returned the most: Idexx Laboratories (IDXX) -3.3%, Phibro Animal Health (PAHC) -6.4%, Zoetis (ZTS) -28.8%. Over five years, Phibro Animal Health (PAHC) compounded fastest (Idexx Laboratories (IDXX) +1.9%/yr, Phibro Animal Health (PAHC) +12.0%/yr, Zoetis (ZTS) -16.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Zoetis (ZTS) has the highest dividend yield: Idexx Laboratories (IDXX) 0.00%, Phibro Animal Health (PAHC) 0.01%, Zoetis (ZTS) 0.03%. Idexx Laboratories (IDXX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Idexx Laboratories (IDXX) has been the steadiest (Idexx Laboratories (IDXX) 35.6%, Phibro Animal Health (PAHC) 55.6%, Zoetis (ZTS) 38.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, IDXX, PAHC and ZTS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.